Social Analytics Toolkit – Amgen

 

Project Overview

Boston University is supporting Amgen in developing and implementing a tailored social analytics toolkit to facilitate measurement and reporting for the company’s access programs.

Social Analytics are a set of tools and methods for understanding and measuring social aspects of private industry-led programs. Barriers to access in low- and middle-income countries are complex and new social innovations are needed to improve access. Social analytics facilitate innovation processes by providing timely information on key aspects of program performance.

Social analytics also facilitate public reporting on company access programs. The Sustainable Development Goals (SDGs), specifically SGD 17, recognize the specific responsibility of the private sector in contributing to global social aims. The pharmaceutical industry has a special role to play in contributing to the SDGs because their products have a direct impact on the health and well-being of populations. Part of this responsibility involves documenting their contributions in a methodologically sound and transparent manner.

 

Key Activities

  • Provide guidance on the development and implementation of a social analytics toolkit for Amgen’s new and ongoing access projects.
  • Develop capacity building resources and carry out trainings with Amgen staff related to adoption of the social analytics toolkit.

 

Agreement

The Master Service Agreement signed by Boston University and Amgen is available here.

 

Related Resources

This project is part of broader effort by Boston University faculty to improve measurement and reporting for pharmaceutical industry-led access programs. This effort includes:

  • The Access Observatory (accessobservatory.org), a public reporting platform for industry-led access programs.
  • A review of strategies and evidence on the impact of industry-led access programs, published in Health Affairs (link)
  • A commentary on the unique opportunity currently available for industry, academia, and global health stakeholders to come together to strengthen institutions for measuring industry-led access programs (link)